Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
But at this price point, with medication included, Henry Meds removes the biggest barrier that keeps uninsured patients from accessing GLP-1 therapy
The largest increases in first-time CVD diagnosis following first-time GLP-1 RA prescription were seen in the group of people having overweight or BMIs between 27 to 30 (34.5% increase from 2020 to 2024)
However, there is only one approved drug, setmelanotide for POMC-LEPR deficiency [10], and there is no treatment for other POMC-MC4R pathway-deficient diseases, such as POMC-null, MSH-deficiency, and patients with PWS with obesity
This story originally appeared on MarketBeat Skye Bioscience (NASDAQ: SKYE) is a micro-cap pharmaceutical company that is striving to become the next big thing in the weight loss drug space
A.PedreaezA.CarreroY.CallejasD
US$ 27.73
US$ 20.88
US$ 29.19
US$ 25.37
